The effect of Cabergoline on blood glucose control in type 2 diabetic patients
Phase 3
Recruiting
- Conditions
- Type 2 diabetes mellitus.Type 2 diabetes mellitus
- Registration Number
- IRCT20100314003565N9
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
A type 2 diabetic patient with a history of at least 3 months receiving metformin at a dose of 2 g / day
Age from 30 to 65 years
HbA1C levels in the range of 7- 8.5
Obtaining Conscious Consent from all Participants involved in the Study
Exclusion Criteria
Pregnancy
The presence of other diseases (cardiovascular, kidney, liver, lung, thyroid and pituitary diseases)
smoking
Taking herbal remedies
Taking other diabetes controller drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fast blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;2-hour postprandial blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;HbA1C. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.
- Secondary Outcome Measures
Name Time Method Cholestrol. Timepoint: Basline and 3 months after the treatment. Method of measurement: Blood Test.;TG. Timepoint: Basline and 3 months after the treatment. Method of measurement: Blood Test.